bluebird bio Inc. (BLUE) - Market Cap to Earnings

bluebird bio Inc. - graphic logo of issuer BLUE

This daily price chart illustrates the price action of bluebird bio, Inc., whose business remains independent of GDP cycles given the critical nature of developing treatments for genetic pathologies. The current P/E ratio is -0.20. The company relies on alliances with clinics and insurers to expand therapy coverage; however, a severe liquidity shortage and narrow specialization necessitate an urgent shift in sales strategy.

BLUE - bluebird bio P/E Multiple over the range 07/04/2022 - 06/07/2025

Comprehensive metric breakdowns and analytics for bluebird bio (BLUE)

- price and consensus price forecast:
- market capitalization indicators:
General company analysis:bluebird bio - BLUE
Flagship merchandise of bluebirdbio.com

The P/E ratio determines the market value of a single unit of profit, reflecting investor expectations for capital return. The metric's value depends directly on quarterly profitability and tax adjustments. By analyzing the P/E multiple under IFRS, one can assess the degree of overpayment for an asset. For bluebird bio, Inc. (BLUE), this indicator is critical due to the high cost of gene therapy. The valuation reflects the monetization potential of unique treatment methods for rare blood diseases.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|NTLA (Intellia) - Company Value to Net Income|Price to Earnings Ratio Stoke STOK|BioLife (BLFS) - Market Cap to Earnings|wavelifesciences.com - P/E Multiple|Market Cap to Net Income MAZE|SION: P/E Multiple|PRME - Business Payback Period|Price to Earnings Ratio TSHA|QURE - Market Cap to Net Income Ratio|P/E Multiple MGTX|Business Payback Period regenxbio.com|P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Earnings Multiple|PACB - Price to Earnings Ratio|Benitec (BNTC) - Price to Earnings Ratio|DSGN: P/E Multiple|RCKT: Market Price to Net Income Ratio|FDMT (4D Molecular Therapeutics, Inc.) - P/E Multiple|lexeotx.com (LXEO) - Business Payback Period|P/E Multiple KRRO|Price to Earnings Ratio Editas Medicine, Inc. EDIT|Price to Earnings Ratio silence-therapeutics.com SLN|PRQR: Price to Earnings Multiple|CDXS - Price to Earnings Ratio|Business Payback Period Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Price to Earnings Ratio|Market Cap to Earnings Metagenomi, Inc. (MGX)|Price to Earnings Ratio DTIL|Price to Earnings Multiple GBIO (generationbio.com)|Price to Earnings Ratio Boundless Bio, Inc (BOLD)|P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Price to Earnings Ratio|PHIO: Price to Earnings Multiple|MBIO - Price to Earnings Ratio|Market Cap to Net Income RNAZ|Bionano Genomics, Inc. (BNGO) - Price to Earnings Ratio|Applied DNA Sciences, Inc. (APDN) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio